Historically, the epidemiology of gastrointestinal diseases in Asia was different from that in Western countries. Early studies suggested a low prevalence of irritable bowel syndrome (IBS) in Asia. As the diagnosis of IBS is symptom-based and as symptom perception, expression, and interpretation are influenced by sociocultural perspectives including language, the presentation of IBS is expected to vary in different communities. Furthermore, the pathogenesis is multifactorial with psychosocial (stress, illness, behavior, and diet) and biological (infection, gut microbiota, and immune activation) variables interacting, and so, the present study can anticipate that the development of IBS will vary in different environments. In recognition of this aspect of functional gastrointestinal disorders, the recently published Rome IV documents have provided greater focus on cross-cultural factors. In this review, the present study seeks to highlight Asian perspectives by identifying historical trends and recent publications from the region and comparing these with the observations from Western societies.
Introduction
Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal (GI) disorder (FGID) that can be continuous or remittent. The clinical phenotype is heterogeneous with various symptom combinations including abdominal pain, bloating, constipation, and diarrhea. In the absence of well-validated biomarkers, diagnosis is based on symptom criteria, and the current standard is the Rome IV criteria, which were published in May 2016. 1 The impact of crosscultural differences, the intestinal microenvironment, and the role of diet were given more prominence in this set of criteria compared with previous versions. 2, 3 With the recognition by the international community that sociocultural and environmental factors may influence the development and manifestation of IBS, it is appropriate to examine the literature from an Asian perspective.
The objective of this literature review is to summarize recent evidence on IBS as it relates to Asian patients. We used as a starting point previous reviews from Asia [4] [5] [6] which were supplemented by articles identified in PubMed using the search terms irritable bowel syndrome, IBS, irritable bowel syndrome and Asia, and IBS and Asia from January 2010 to May 2016. In addition, each of the authors identified references known to them from their respective areas of research within Asia.
Epidemiology
The prevalence of IBS varies between geographic regions and populations and is also dependent upon the diagnostic criteria used (Fig. 1) . 2 Cross-sectional studies from Europe and North America showed IBS to affect 10-20% of the population. Using Manning, Rome I, Rome II, or Rome III criteria, a global prevalence for IBS of 11.2% was reported. 7 In the largest analysis to date, involving 41 countries, 83 studies, and 288 103 subjects, the mean prevalence among individual countries ranged from 1.1% in France and Iran to 35 .5% in Mexico. 2 Prevalence rates according to diagnostic criteria were as follows: Rome I, 6.7%; Rome II, 7.8%; Rome III, 9.1%; Manning, 8.3%; and no specified diagnostic criteria 12.8%. The rate was higher in women compared with men (10.2% vs 8.8%), and the mean age was 40.0 (95% confidence interval [CI] 31.2-51.0) years.
Early studies from Asia reported a prevalence of IBS below 5%. 8 Prevalence rates ranging from 6.8% to 33 .3% have been noted in more recent (post-2013) studies from the region (Table 1) . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Across Asia, IBS is more prevalent in younger age groups, but, unlike in Western studies, IBS is equally common in men and women. 4, 8 The latter trend is supported by a closer examination of the data presented by Sperber et al. 2 and in clinic-based and communitybased studies in India. 18, 19 Overall, these findings consistently show equivalent prevalence of IBS in men and women in Asia.
In multiracial societies such as Singapore and Malaysia, the prevalence of IBS was comparable in the different ethnic groups (Chinese, Indians, and Malays). 15 The highest prevalence was observed among educated and more affluent people. 4 A study from Pakistan found that men in the top socioeconomic status with a low education level, that is, from "rags to riches," had the highest IBS symptom scores. 20 
Disease burden
Irritable bowel syndrome places an enormous burden on resourcechallenged healthcare systems. Medical costs for IBS patients were 50% higher than the equivalent costs for non-IBS patients. Increased costs were driven more by frequent use of medical services, including care not directly related to lower GI problems, rather than the cost of prescriptions. 22 Studies that measured quality of life (QoL) in Asian IBS patients, using instruments such as the short-form-36, IBS-specific QoL questionnaire, and EuroQol-5 Dimension questionnaire (EQ-5D), are summarized in Table 2 . [23] [24] [25] [26] [27] In China, South Korea, and Singapore, IBS had a marked negative impact on QoL and disease burden. In Korea, a cross-sectional study using the National Health Insurance database found that 6% of the population sought medical care for IBS at least once per year. IBS outpatients had an average of 2.5 outpatient visits per year, inpatients had an average of 15 days in hospital, and diagnostic tests were frequently repeated. 28 In total, IBS accounted for about 0.5% of total medical expenditure in Korea. 28 A combination of intestinal symptoms and comorbid psychological factors affected the QoL of patients with diarrhea-predominant IBS (IBS-D), with the impact differing by gender. In female patients, comorbid psychological disorders were more significant, and the effects of food avoidance and social reactions were more obvious. 24 Variations in healthcare provision can affect how IBS and other FGIDs are managed. A Rome Foundation Working Team compared the management of FGIDs in four different healthcare systems (India, Italy, Mexico, and South Korea). 29 Italy and South Korea have effective universal healthcare coverage whereas India and Mexico spend less on health care, negatively impacting both diagnosis and management. In Italy, medications for FGIDs are not covered by public healthcare services. In South Korea, where all expenses pertaining to FGIDs tend to be covered, doctors cannot prescribe psychotropic drugs without a psychiatric diagnosis thus limiting their use in IBS.
Symptomatology
Cultural differences in the interpretation of symptoms and inappropriate translation of study questionnaires may contribute significantly to the heterogeneity between studies. Experts noted that terms such as constipation, bloating, and fullness are difficult to define and differentiate from each other. 30 Bloating is primarily an English term, whereas in most other cultures, the term distension is used for the same symptom. Postprandial fullness, bloating, and the relative severity of abdominal pain may not be interpreted in the same way in different countries. 31 The frequency of different IBS symptoms varies in different geographic locations (Table 3) . 31 The highest rates of abdominal pain and bloating were reported in Italy (the least urban population) and the lowest in Calcutta, India (the most urban). Mexico had the highest rate of constipation-predominant IBS (IBS-C) and lowest rate of IBS-D, whereas China had the highest rate of IBS-D and second lowest rate of IBS-C. Cultural beliefs, gut contamination, urban versus rural location, dietary practice including vegetarianism, and psychosocial reasons, may contribute to these differences. Asian countries tend to have more peptic ulcer, gastric cancer, and lactase deficiency but less inflammatory bowel disease, celiac disease, and reflux oesophagitis. 3, 5, 32, 33 Chinese and Indian IBS patients tended to localize pain more to the upper abdomen than the lower abdomen. 4, 32, 34, 35 A pan-Asian survey found that 62% of patients with IBS had an overlapping FGID diagnosis; in the majority of cases, it was functional dyspepsia (FD). 36 Recent studies from South Korea, China, and Bangladesh reaffirm the high degree of overlapping FD in IBS. 17, 35, 37 Compared with the general population (adjusted for gender and age), IBS patients scored significantly lower on all SF-36 scales (P < 0.001) except for physical function (P = 0.149). The greatest decreases in QoL were in the domains for vitality, general health, mental health, and bodily pain. Patients with IBS-C scored significantly lower for physical function, role physical, general health, role emotional, and mental health (all P < 0.05) than patients with IBS-D.
These results confirm that IBS has a broad significant negative impact on the QoL of consulting patients with IBS in China.
The overall IBS-QoL score was 71.7 ± 18.5, and the three lowest scores were for food avoidance (53.7 ± 26.9), dysphoria (65.0 ± 24.4), and health worries (67.4 ± 22.7). Females had lower scores on all eight domains versus males, and for food avoidance and social reaction, the differences were statistically significant. Anxiety (HAM-A) and depression (HAM-D) were negatively with overall QoL as determined by the IBS-QoL score in this study.
A combination of intestinal symptoms and comorbid psychological factors contributed to deterioration in QoL in patients with IBS-D. Gender-related differences were noted in this study, and these may have implications for treatment.
South Korea 25 
SF-36 IBS-C 12 IBS-D 13 IBS-A 6 {Rome II}
In this population study, 2.2% had IBS. Patients with chronic GI disease (dyspepsia, GERD, and IBS) had significantly impaired QoL compared with subjects without GI disease. IBS patients had the lowest scores for vitality, role emotional, and mental health. In general, the negative impact on QoL was greater in females, the elderly, subjects from a lower socioeconomic class, and in those with a higher number of physician visits or overlapping symptoms.
The presence of chronic GI symptoms was shown to have a negative impact on the QoL of Korean patients with dyspepsia, GERD, and IBS. On all eight of the SF-36 domains, IBS patients had significantly worse HRQoL than the general population (P < 0.01). Female IBS patients reported a lower HRQoL than male patients. Using the IBS-QoL questionnaire, health concerns and food avoidance were most affected, and sexuality and relationships were the least affected. In a multivariate analysis, the IBS-QoL was significantly associated with female gender, total symptom score, self-reported symptom severity, and education level.
IBS-related symptoms had a marked effect on QoL in Korean patients with IBS. In light of the high prevalence of IBS in Korea, this disorder has a substantial social impact on the country.
Singapore 27 EQ-5D IBS 198 {Rome III}
The mean EQ-5D score was 0.74 in patients with IBS versus 0.84 for a non-IBS group. After adjustment for age, gender, and presence of significant illness in another family member, the effect of IBS on EQ-5D was statistically significant (À0.11 95% CI À0.15 to À0.07; P < 0.001). There was a significant association between IBS and four of the five EQ-5D dimensions; mobility, anxiety/depression, usual activity, and pain.
IBS has a significant negative effect on QoL.
Abbreviations: CI, confidence interval; EQ-5D, EuroQol-5 Dimension questionnaire; GERD, gastroesophageal reflux disease; HAM-A, Hamilton Rating Scale-Anxiety; HAM-D, Hamilton Rating Scale-Depression; IBS, irritable bowel syndrome; IBS-A, alternating-type; IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; IBS-M, mixed-type IBS; IBS-QoL, IBS-specific quality of life questionnaire; QoL, quality of life; SF-36, short-form-36.
Natural history
The natural history of IBS includes exacerbations and remissions with some patients developing new symptoms within the FGID category. 38 While the overall prevalence of FGIDs remains relatively stable over time, there is a high turnover in symptom status. In two studies, approximately 40% of patients had different symptoms and/or changed their FGID subgroup over 10-12 years. 39, 40 In a Swedish study involving over 1000 patients with FGIDs, those suffering with reflux, dyspepsia, and IBS symptoms in the first survey reported the same symptoms in 61%, 32%, and 55% of cases after 1 year, and in 29%, 30%, and 55% of subjects after 7 years. 38 In parallel with a decrease in the number of patients reporting reflux symptoms, there was an increased number with no or mild symptoms (61%). Patients reporting IBS rarely developed reflux (≤ 4% at each follow-up) and were more stable in terms of the primary indication (55% at 1 and 7 years). In Asia, studies on the natural history of IBS are lacking.
Diagnosis
Symptom-based criteria initially proposed by Manning for the diagnosis of IBS were subsequently modified into various iterations of the Rome criteria (Table S1) . [41] [42] [43] [44] [45] A Canadian center analyzed the performance of these symptom-based criteria in 4224 consecutive patients in secondary care and found a specificity of between 71% and 82%, suggesting that they were modestly and similarly effective in distinguishing IBS from organic GI disease. 46 Despite a high prevalence of IBS in the study population, the predictive value for the four sets of criteria was < 50%, indicating that more accurate diagnostic methodologies are required. A similar study in India involving 1632 patients with chronic lower GI symptoms and no alarm features and also using criteria developed from the Asian consensus showed the following sensitivity for the various criteria: Manning (91%), Rome I (68%), Rome II (40%), Rome III (53%), and Asian (75%). 32 These results show that the Rome criteria, especially Rome II, were too insensitive for IBS in India compared with Manning criteria (91.2% positive) and the Asian criteria (74.5% positive). In recently published pan-Asian studies, a high degree of overlap was observed between FD and IBS that could have impacted on treatment. Novel symptom clusters were uncovered, many of which represented possible overlap between upper and lower GI symptoms.
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Pathophysiology
The pathogenesis of IBS is multifactorial including alterations in the gut microbiota, small intestinal bacterial overgrowth (SIBO), visceral hypersensitivity, intestinal mucosal immune activation, dietary intolerance, increased intestinal permeability, disruption of the gut-brain axis, psychosocial distress, and altered GI motility. Figure 2 illustrates how an individual patient may have multiple factors combining to develop IBS. It also illustrates how investigators or healthcare professionals may choose to focus on only one aspect of the patient's problem.
Post-infectious IBS (development of IBS following an episode of acute gastroenteritis) is a well-recognized entity, with early studies from the UK implicating Salmonella and Campylobacter spp. 48, 49 In Asia, Shigella spp. were more commonly reported. 50, 51 As in Europe, Asian patients with post-infectious IBS demonstrated increased mucosal T-lymphocytes, mast cells, and enteroendocrine cells, which supports an inflammatory-immunemediated mechanism in the development of IBS. 51, 52 Disturbances in the gut microbiota (gut dysbiosis) may be involved in the development of IBS via mechanisms such as the following: increasing the adhesion of enteric pathogens within the intestine; disturbed colonic fermentation; or alteration of the bacterial ecosystem. 53 Symptom improvement among IBS patients treated with antibiotics provides support for involvement of the microbiota. 54 Several studies employing lactulose or glucose hydrogen breath testing showed a link between SIBO and IBS. 55 However, a jejunal aspiration study reported that the increase in small bowel bacteria in IBS patients was generally much milder than is found in classical SIBO. 56 Ghoshal and Srivastava reported a worldwide prevalence of SIBO in IBS of 4-78% with a rate of 8.5-23.7% in Asian studies. 57 Such variation might be explained by geographical differences, IBS diagnostic criteria, or importantly, the methods used to diagnose SIBO. Female Figure 2 Irritable bowel syndrome (IBS) is a multifactorial disorder. Elephants are symbolic of much of Asia, the region under review. It reminds us of the message from the story of the "blind men and an elephant" in which a group of blind men touch a different part of an elephant to learn what it is like. They then compared notes and found complete disagreement. This is somewhat akin to the many views relating to the etiology and pathophysiology of IBS! gender, older age, IBS-D, marked bloating and flatulence, proton pump inhibitor usage, narcotic intake, and low hemoglobin levels have all been shown to be associated with SIBO in patients with IBS. 57 Several techniques are available for the diagnosis of SIBO with the non-invasive lactulose hydrogen breath test and glucose hydrogen breath test being the most commonly used. However, these tests lack precision and are influenced by GI transit times. 57 A US study concluded that more than three-quarters of patients with IBS had SIBO based on a rise in breath hydrogen by 20 parts per million above the basal level within 90 min of ingestion of the test substrate. 55 The orocecal transit time in healthy subjects from several Asian populations is actually shorter than 90 min, 4 and so, this would not be a suitable test for SIBO in Asian patients. 57 In a case-control study involving 221 patients with IBS and 273 age and gender matched-controls in India, the presence of an interleukin-1 (IL-1) receptor antagonist under-producer genotype was associated with IBS, and the converse was true for the over-producer genotype. 58 Furthermore, higher levels of IL-1α and IL-1β were found in patients with SIBO, and IL-1β was associated with bloating and loose stools. These findings point to a positive association between low-grade inflammation and IBS. 58 Exacerbation of symptoms, either as a direct or delayed reaction to food intake, has been reported by more than half of IBS patients; with particular foods frequently cited as a trigger for such symptoms. 59 The term food intolerance describes non-immune-mediated reactions to food, which resolve following dietary elimination and are reproduced by rechallenge. 60 This includes the direct effects of constituents of foodstuffs (e.g. lactose and fructose intolerance).
Food allergy/hypersensitivity is used to describe conditions in which immunological mechanisms may be demonstrable (e.g. peanut, cow's milk, and soybean allergy). An immunemediated food hypersensitivity response involving IgE or IgG antibodies was hypothesized as the underlying mechanism in a proportion of patients with IBS. 60 These researchers found an elevated IgG4 antibody response to common foods such as wheat, beef, pork, and lamb in 108 IBS patients, whereas no such reaction occurred for IgE. In a parallel study, they showed that an IgG4 food antigen-directed exclusion diet in 25 IBS patients resulted in improved symptoms such as pain severity (P < 0.001), pain frequency (P = 0.034), bloating (P = 0.001), bowel habits (P = 0.004), and general well-being (P = 0.008) after 3 months. 61 In China, Zuo et al. compared serum food antigen-specific IgG and IgE antibodies in controls and patients with IBS. 62 While IgG antibody titers for some foods, for example, crab, shrimps, eggs, soybean, and wheat, were increased in IBS patients compared with controls, there was no significant correlation with symptoms. Non-celiac gluten or wheat sensitivity is increasingly reported in the west among IBS subjects; there are now also reports from Singapore, China, and India of this phenomenon among IBS subjects. 63, 64 In terms of dietary intolerance, a group of poorly absorbed short-chain carbohydrates including fructose and lactose, fructans, galacto-oligosaccharides, and polyols or sugar alcohols described under the acronym FODMAPs (fermentable oligo-, di-, and monosaccharides and polyols) is of particular current interest. These carbohydrates can cause IBS symptoms via two main mechanisms: firstly, their osmotic activity and poor absorption by the small intestine can lead to net secretion of fluid with consequent distension and abdominal symptoms; secondly, FODMAPs are rapidly fermented by the colonic microbiota, leading to colonic distention from gas production, with associated pain and bloating. 65 In rural northern India, vegetarianism is a risk factor for IBS, 19 possibly related to the high content of FODMAPs, including milk products, in the vegetarian diet.
In an Indian study involving 184 adult outpatients with IBS and 198 healthy controls, psychiatric comorbidity was more common in the IBS group: major depressive syndrome (47.3 vs 5.1%; P < 0.001), somatoform disorders (50.0 vs 14.6%; P < 0.001), and panic attacks (44.0 vs 11.6%; P < 0.001). 66 An increased incidence of anxiety (38.6% vs 24.2%; P < 0.05) and depression (38.6 vs 16.5%; P < 0.05) was observed in 124 IBS patients compared with healthy subjects in Korea. 67 Self-reported symptom severity was a key predictor of anxiety and depression and was also related to impairment of QoL. In a Malaysian study in which 248 patients underwent endoscopic examination for symptomatic FGID, anxiety was significantly more common in patients with IBS compared with healthy controls (67.7% vs 14.5%; P < 0.001) and patients with FD (43.5%; P = 0.01) or non-erosive reflux disease (45.2%; P = 0.02). Depression was also significantly more frequent in the IBS group compared with the control group (38.7% vs 6.5%; P < 0.0001), but there was no significant difference between the three FGID groups. 68 Both experimental and clinical findings suggest that psychological stress impacts on intestinal sensitivity, motility, secretion, and permeability, while also having a close correlation with mucosal immune activation, alterations in the CNS, peripheral neurons, and the GI microbiota. 69 There is recent evidence for a bidirectional relationship between the gut and brain. In a prospective longitudinal study involving 1775 participants, subjects with FGID at baseline, but without anxiety, had a greater risk of developing anxiety during a 12-year follow-up. 70 Further analysis of the same population cohort 1 year later showed that a mood disorder preceded FGID in one-third of patients, whereas in the other two-thirds FGID preceded the mood disorder. 71 A study from China found no differences between psychological factors and intestinal symptoms in their impact on QoL of IBS-D patients. 24 A study from Japan found no differences in anxiety, depression, and stress ratings between consulters and nonconsulters. 72 Collins et al. suggested that a microbe-gut-brain axis could explain the pathophysiology of IBS. 73 In this model, triggers such as infection, stress, and antibiotics initiate microbial changes that, in turn, alter host physiology. Consequent changes in gut motility, hormone secretion, and mucin production modify the physicochemical properties of the intestinal niche and its microbial composition, creating instability in the gut microbiota. Thus, a self-perpetuating vicious cycle characterized by chronic gut dysfunction and instability of the gut microbiota is established. Fluctuations in the microbial composition of the gut might account for the changes in symptom profile over time that occur in some IBS patients.
Management
Lifestyle modification is a popular starting point in the management of IBS, and common measures include regular exercise, reduced alcohol intake, dietary changes, and regular sleeping habits. Scientifically rigorous studies to support the benefit of exercise in IBS are few, but exercise may speed up colon transit times and increase bowel movement. 74 As many IBS patients identify food as a trigger for their disease, exclusion diets are important. Dietary management has progressed beyond the old ideas of fiber treatment. In fact, recent studies suggest that dietary fiber-rich foods may exacerbate bloating and flatulence. 75, 76 In a randomized, single-blind, cross-over study in 30 patients with IBS and eight healthy controls, symptom scores were halved in subjects with IBS on a low-FODMAP diet compared with an Australian diet. 76 With regards to the Asian diet, rice is probably the best source of carbohydrate for subjects with FGIDs because of its low allergenicity, almost complete absorption in the small bowel, low gas production, and its low fiber content. 75 The effects of chili and its active ingredient capsaicin are of interest among Asians given their predilection for spicy food. While acute exposure can aggravate abdominal pain and burning in IBS patients, Gonlachanvit suggests that chronic ingestion of chili may serve to desensitize capsaicin receptors that play a role in the gut irritability associated with FGIDs. 75 Antispasmodics remain first-line therapy for abdominal pain in patients with IBS. The availability of antispasmodic agents differs from country to country, and a list of commonly available compounds in Asia, Europe, and the USA is provided (Table 4 ). Antispasmodics include several different classes of drugs such as the smooth muscle relaxants (e.g. mebeverine), anticholinergic agents (e.g. butylscopolamine and hyoscine), and calcium channel blockers (e.g. otilonium and pinaverium). [77] [78] [79] In a meta-analysis of the use of 12 different antispasmodics in 22 clinical trials involving 1778 patients with IBS, the relative risk (RR) of persistent symptoms was 0.68 (95% CI 0.57 to 0.81) compared with placebo. 78 Otilonium (four trials, 435 patients: RR of persistent symptoms 0.55, CI 0.31 to 0.97) and hyoscine (three trials, 426 patients, RR 0.63, 0.51 to 0.78) were most consistently efficacious. In a more recent meta-analysis, Martinez-Vázquez et al. reported that otilonium and alverine/simethicone produced significant global improvement in patients with IBS. 79 A study involving otilonium suggests that the improvement on treatment could persist after discontinuation. 77 At the end of 15 weeks' treatment, otilonium produced significantly greater improvements in reducing frequency of pain, reducing severity of abdominal bloating, and increasing global symptom relief compared with placebo. During 10 weeks' follow-up after withdrawal of treatment, otilonium appeared to offer protection from symptom relapse as its therapeutic effects remained greater than that of placebo, with significantly greater relapse-free probability. 76 Another treatment that appears to produce similar protection from symptom relapse is the non-absorbable antibiotic rifaximin, which has been approved by the FDA for the treatment of IBS-D. Rifaximin is a rifamycin-derived antibiotic that acts to reduce SIBO, may modulate colonic flora, and may also have an antiinflammatory immune modulating effect. 80 An anecdotal report from India suggested that rifaximin could improve symptoms even in patients with IBS-C. 81 Probiotics provide a modest benefit in IBS. 82, 83 Possible mechanisms include increased mass of beneficial bacteria in the GI tract, reversal of the imbalance between the pro-inflammatory and anti-inflammatory cytokines, reinforcement of the intestinal mucosal barrier, decreased small intestinal permeability, and normalization of digestive tract motility and its visceral sensitivity. 82, 83 Caution should be exercised in extrapolating the positive effects of specific probiotics to the general class as not all formulations have been shown to improve IBS. 82 The addition of prebiotics could have a detrimental effect by inducing fermentation and gas production.
Therapy targeting constipation could be useful not just for constipation but also to improve bloating and abdominal pain in IBS-C. 84 Prucalopride, a prokinetic selective 5-HT 4 agonist, has been shown in Asian populations to improve both constipation and bloating. 85 Although prominent side effects include diarrhea, headache, abdominal pain, and nausea, no cardiovascular safety concerns have been reported. 86 A new class of agents called colonic secretagogues includes chloride channel stimulators (lubiprostone), and guanylate cyclase agonists (linaclotide) has been introduced for treating chronic constipation. While linaclotide has been approved by the US FDA for the treatment of IBS-C, there is as yet no published Asian data, although a phase 3 trial is ongoing in China. 87 For lubiprostone, clinical findings from Japan support US data, which demonstrated a significant improvement in abdominal pain, abdominal discomfort, abdominal bloating, severity of constipation, lumpy stool, and straining in IBS-C patients. The overall bias in this meta-analysis was low. SJZT produced significant improvement in global symptoms compared with placebo (RR 1.61; 95% CI 1.24, 2.10; P = 0.0004). The therapeutic gain was 33%, and SJZT was significantly more likely to reduce Symptom Severity Scale scores (P < 0.00001) and improve abdominal pain (P < 0.00001). Gastrointestinal symptom rating scale scores were lower in the H-P and F-P moxibustion groups than the pinaverium group at week 4 and week 8. H-P moxibustion produced greater relief of abdominal pain (P < 0.01), abdominal distension (P < 0.01), rugitus (P < 0.05), and increased passage of stools (P < 0.01) than pinaverium. While all treatments significantly improved IBS symptom scores, QoL, and depression/anxiety scale scores (all P < 0.001), the optimal results were achieved with application of one cone three times per week. SGIP acupuncture was found to be superior to pinaverium in terms of a more rapid onset of action (P < 0.05), better symptomatic improvement (abdominal pain, diarrhea, abdominal distension, etc.), and enhanced QoL (P < 0.01). EAP and moxibustion were both effective in improving IBS symptoms. EAP was more effective in patients with IBS-C (P < 0.01) and moxibustion in patients with IBS-D (P < 0.01).
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Xing et al.
107 IBS (n = 60) Rome III
Spinal orthopedic manipulation five treatments Pinaverium bromide 50 mg tid for 2w R, P-G IBS symptom scores in the spinal orthopedic manipulation group were significantly lower than those in the pinaverium group. Symptom improvement ratings of good/excellent were recorded in 27 patients in the spinal orthopedic manipulation group and 15 cases in the pinaverium group (P < 0.001).
Abbreviations: bid, twice daily; bw, bi-weekly; D-B, double-blind; EAP, electroacupuncture; FD, functional dyspepsia; F-P, farina-partitioned; H-P, herbpartitioned; IBS-C, constipation predominant IBS; IBS-D, diarrhea predominant IBS; P-C, placebo-controlled; P-G, parallel-groups; R, randomized; RR, relative risk; SGIP, Soothing Gan and Invigorating Pi; tid, three times daily; w, weeks.
Agents that target diarrhea include 5-HT 3 -receptor antagonists (e.g. ramosetron and ondansetron), which can slow colonic and small bowel transit and decrease intestinal secretion and colonic tone, and locally active mixed m-opioid agonist / d-opioid antagonist (e.g. eluxadoline). [90] [91] [92] In male and female Japanese patients with IBS-D, ramosetron improved stool consistency and relieved abdominal pain. 91 Psychotropic agents are widely prescribed to IBS patients in the United States although less often used elsewhere. A primary care US health maintenance organization analysis found that antidepressants and anxiolytics were prescribed to 55% and 45% of patients with IBS; 93 and this compared with 16% and 8% of patients, respectively, in a survey of primary care gastroenterologists in Italy. 94 Seventy percent of Asian gastroenterologists would only use a psychotropic agent as second-line treatment. 95 A recent survey from Asia found that only about 20% of patients were prescribed psychotropic agents. 47 Traditional Chinese medicine Table 5 presents details and some key findings from recent studies employing traditional Chinese medicine (TCM). [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] Three evidence-based meta-analyses of Chinese herbal medicine (14 randomized controlled trials (RCTs), 1551 patients), 97 moxibustion therapy (seven RCTs, 568 patients), 102 and Shugan Jianpi Zhixie therapy (seven RCTs, 954 patients) 99 highlight some promising findings with TCM. However, study limitations (small sample sizes and masking) and the heterogeneity of Chinese herbal mixtures/practices limit the ability to draw strong conclusions from these meta-analyses. Kampo, a form of TCM, is widely adopted in Japan; a review by Oka et al. described a compound known as keishikashakuyakuto with limited data from two clinical trials reported only in the Japanese literature. 108 One study from Germany examined the herbal preparation STW 5 (nine plant extracts) in a double-blind RCT-reported efficacy for alleviating abdominal pain in IBS. 109 
Conclusions
Since our last reviews in 2009 and 2010, 4, 5 there has been an explosion of new understanding of the pathophysiology and of new treatments in IBS. There is also encouraging growth of research from Asia, with more studies highlighting differences between the East and West. However, as these differences have not been validated by head-to-head comparisons, it is possible that they reflect differences in emphasis determined by geography, culture, and environment. Nonetheless, these observations provide "food for thought," which we hope may inspire novel future research questions.
